Cytlimic
About:
CYTLIMIC is a biotechnology company that develops immunotherapy products for the treatment of cancer, including a cancer peptide vaccine.
Website: https://cytlimic.com/en
Top Investors: SMBC Venture Capital, Fast Track Initiative, Inc., NEC Capital Solutions
Description:
CYTLIMIC is a biotechnology company developing immunotherapy products for the treatment of cancer, including a cancer peptide vaccine. CYTLIMIC’s products aim to activate immune systems to attack cancer cells while enabling patients to maintain a high quality-of-life during treatment.
Total Funding Amount:
2.3B JPY
Estimated Revenue Range:
$1M to $10M
Headquarters Location:
Higashi-shinagawa, Tokyo, Japan
Founded Date:
2016-12-16
Founders:
Shun Doi
Number of Employees:
11-50
Last Funding Date:
2019-08-09
IPO Status:
Private
Industries:
© 2025 bioDAO.ai